Strong demand for high-quality, affordable generics is expected to continue growing as governments manage their healthcare budgets in the face of increased pressures. We are strategically positioned to capture significant opportunities in this dynamic market environment.
Our business model
Our diversified business model enables us to respond to the many opportunities and challenges we face, while delivering value for our patients, employees, shareholders and wider communities.
Our strategy
Our strategy is to deliver high-quality and affordable generic and branded generic medicines to patients.
Why invest
With our unique and established capabilities and strategy for growth, we offer a clear proposition to investors.
Related news
Hikma Board Appoints Cynthia Schwalm as Director
12 March 2019
Notice of results
26 February 2019